Introduction: Multiple myeloma (MM) is a bone marrow plasma cell malignancy characterized by
Introducing multiple myeloma
Multiple myeloma (MM) is a malignant proliferation of antibody-secreting bone marrow (BM) plasma cells (PCs) that accounts for 10% of all hematological malignancies with an incidence in
Western countries of about 3-5 per 100,000. PC dyscrasias show a wide clinical presentation spanning from the presumed pre-malignant condition of monoclonal gammopathy of undetermined significance (MGUS) to smoldering MM (SMM), symptomatic MM, and extra-medullary MM or plasma cell leukemia (PCL) [1] . PCL can be primary (pPCL) if originating de novo without any previous experience of MM, or secondary (sPCL) when arising from a preexisting myeloma tumor that eventually progressed to the leukemic phase [2, 3, 4] .
Similarly to the clinical course, also the genetic background of the disease is highly heterogeneous as featured by a deep genetic instability, at both karyotypic and mutational level.
Karyotypic instability involves structural and numerical aberrations [1, 5] . About half of MM patients are hyperdiploid, carrying non-random trisomies of odd chromosomes and small incidence of chromosomal translocations at the immunoglobulin heavy chain (IGH) locus (14q32). The other cases are non-hyperdiploid and often display the constitutive activation of CCND1 (11q13), CCND3 (6p21), MAF (16q23), MAFB (20q11), or FGFR3/MMSET (4p16.3) genes, resulting from IGH translocations. Hyperdiploidy typically implies a better outcome, while t(4;14) and t (14;16) translocations are related to a dismal prognosis. In addition, imbalances of specific chromosomal portions including 17p13, 1p, 16q, 14q losses and 1q gains are negative prognostic factors [1, 6, 7, rationale behind the efforts to characterize the genetic landscape of MM cells made in the recent years by means of next generation sequencing technologies (NGS). Here, we describe how NGS has improved our knowledge of MM biology by discovering its mutational landscape, identifying the mutational processes operative in the disease, and revealing its complex clonal composition and evolution. Furthermore, we discuss the clinical implications of NGS in terms of prognostication, therapeutic choices, and response assessment in the disease. Finally, we provide a quick outlook of future applications of these technologies that could contribute to further dissect the biology of MM cells and help in the management of the disease in the next future.
2.
Whole-genome and whole-exome sequencing findings in MM
Mutational landscape
Three main studies analyzed large cohorts of MM patients by means of whole genome sequencing newly diagnosed MM patients enrolled in the UK National Cancer Research Institute Myeloma XI trial [15] .
The emerging scenario from these studies indicates only a few genes found mutated at a significant frequency in each of the analyzed cohorts, some of which highlighting key pathways commonly deregulated (Figure 1 ).
KRAS and NRAS kinases are by far the most frequently mutated genes in MM (on average in 23%
and 21% of patients, respectively). Along with BRAF ( Figure 2 ), mutated to a lesser extent (8.7% of cases) but still at high statistical significance, they contribute to make the mitogen-activated protein kinase (MAPK) pathway the main target for somatic mutation in MM, as confirmed by a targeted resequencing analysis on a large representative panel of patients at different stages of PC dyscrasia [16] . Notably, the classic V600E variant is carried by less than half of the BRAF-mutated
patients, unlike what observed in other tumor types, i.e. melanoma, colorectal cancer, and papillary thyroid carcinoma. Mutations in the RAS/MAPK pathway are reported to have no impact on survival [15] .
The involvement in MM of DIS3 and FAM46C, which are two of the most recurrently mutated genes in the disease (average mutation frequency of 6.8% and 9.1%, respectively) ( Figure 3 ), was totally unexpected prior to the application of massively parallel sequencing. DIS3 belongs to the human exosome complex; it is endowed with both exo-and endonucleolytic activities and regulates the processing and amount of all RNA species [17] . Although the significance of its alteration in the disease still needs to be further elucidated, it is considered a potential tumor suppressor in MM based on several findings: the loss of enzymatic activity caused by the MMassociated DIS3 mutations that have been functionally characterized [18] ; the loss of heterozigosity often involving DIS3 due to simultaneous gene mutations and chromosome 13 deletion [19] ; and the reported enhanced translation of crucial oncogenes following DIS3
inactivation [20] . Similar to DIS3, FAM46C is an RNA-binding protein whose exact functions remain to be characterized, but potentially regulating gene expression [21] . FAM46C too has a putative tumor suppressor role in MM, as suggested by the deletion of its genomic locus at 1p12, occurring in approximately 20% of MM patients [22] , and the predominantly inactivating nature of MMassociated gene mutations [23] . Overall, the significantly recurrent alteration of DIS3 and FAM46C
suggests a role of translational control processes in the pathogenesis of MM [12] .
Based on the three studies considered above, the process of B cell differentiation resulted frequently targeted by mutational events. Particularly affected were the genes encoding the SP140 nuclear body protein, i.e. the interferon-inducible lymphoid-restricted homolg of SP100; the lymphotoxin beta LTB, that is involved in physiological lymphoid development and in the induction of the inflammatory response system; and the transcription factors PRDM1 and IRF4, essential to plasma cell differentiation. Average mutation rates of SP140, LTB, PRDM1 and IRF4 genes are of 3.6%, 2.8%, 1.6% and 1.5%, respectively. Notably, mutations affecting IRF4, a target of the IMID drugs whose inhibition is toxic to MM cell lines [25] , are preferentially represented by the K123R variant and have been reported to have a positive impact on survival in the Myeloma XI trial [15] .
EGR1 is a transcriptional regulator inducing apoptosis in MM cells, where its knockdown enhanced resistance to Bortezomib [26] . Similarly to IRF4, EGR1 is an IMID target whose mutations, detected in 4.3% of MM patients and clustered at the 5' end of the gene, were found correlated with good overall survival by Walker and colleagues [15] .
The identification of mutations in multiple components of the NF-ĸB signalling (especially TRAF3, with an average mutation rate of 3.9%, CYLD, mutated in 2.6% of cases, and the aforementioned LTB) further supported and extended the anticipated role of this pathway [27, 28] and widened our knowledge on the mechanisms of its activation in MM.
Among the genes found mutated in MM patients, some are involved in cell cycle regulation, in particular RB1 and CCND1, altered respectively in 1.3% and 2.7% of patients; this latter seems to be associated with a negative impact on survival [15] .
Mutational signatures
Two main studies employed non-negative matrix factorization (NMF) to extract mutational signatures from WES data and shed light on the mutational processes contributing to the MM mutational landscape [14, 29] [14, 29] , and their role in myeloma pathogenesis remains to be elucidated.
Finally, the examination of mutational signatures over time in a small fraction of patients indicated that the relative contribution of diverse mutational processes involved in the generation of the mutational repertory in MM may change over time [14] .
Clonal heterogeneity
Massively parallel-sequencing studies [13, 14] intraclonal heterogeneity appears to be a premature event in myelomagenesis, already present before the occurrence of clinical symptoms, suggesting that immortalized plasma cells diverge very early in their evolution. Intra-tumor diversity is critical for disease progression, being the essential substrate for underlying Darwinian-like tumor evolution, as discussed further in the following paragraph.
Clonal evolution
The application of massive parallel sequencing revealed a previously unsuspected model of clonal stability (i.e. no change in the clonal composition), linear evolution (i.e. the emergence of a new subclone), and differential clonal response. This latter pattern consists in an alteration of the relative proportions of each subclone which may be related to their random drift in the course of time; different response to therapy among subclones; or subclone expansion due to selective advantage [14] .
To gain further information about the pattern of evolution underlying relapse in MM, a recent longitudinal study investigated by WES, gene expression profiling and high-resolution copy number arrays 33 patients enrolled in Total Therapy protocols with the aim to define specific drivers of relapse in the precise context of a standard treatment [31] . Notably, the acquisition/expansion of mutations in known MM driver genes (NRAS, KRAS, BRAF) and the biallelic inactivation of tumor suppressor genes, especially TP53, proved to be critical events driving relapse through the escape form treatment-induced apoptosis and increased proliferation, leading to drug resistance and tumor progression. In particular, biallelic events resulting in complete inactivation of TP53 defined the group with the worst outcome after relapse. The excess of biallelic events and copy number changes from presentation to relapse in high-risk cases were consistent with increased genomic instability associated with these patients. The Authors proposed a model combining "Big Bang" and Darwinian type of evolution, in which "Big Bang" dynamics lead to the early establishment of intratumor heterogeneity, followed by Darwinian-type evolution, in which different subclones acquire additional aberrations and compete with each other and normal hematopoiesis to access to an appropriate bone marrow niche. In this scenario, treatment generates a significant evolution bottleneck, which eradicates some subclones but may simultaneously select for clones with strong driver events that increase proliferation and resistance to apoptosis.
Finally, it is worth reporting that a very recent analysis of the distributions of variant allele frequencies determined from WES data of 463 patients from the UK Myeloma XI trial indicated that 
Clinical implications of NGS-derived data
The information made available by the application of NGS technologies in MM has potential relevance in the clinical setting at various levels, including prognostic stratification, therapeutic choices and response assessment.
Prognostication
To date, the potential of NGS in MM prognostication has not yet been fully exploited. In fact, the prognostic significance of the mutational spectrum characterizing MM has been assayed virtually only by Walker and colleagues within the clinical trial Myeloma XI, comparing a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide with a newer regimen of cyclophosphamide, dexamethasone plus lenalidomide [15] . In the context of this study, while mutations in MAPK and NF-ĸB pathways, as anticipated above, are prognostically neutral, variants in CCND1 and DNA repair pathway correlate with poor survival, and those in IRF4 and EGR1 appear to be associated with better prognosis. Notably, some of these new prognostic factors (including mutations in TP53, ZFHX4, CCND1, ATM and ATR) were combined with adverse cytogenetic abnormalities, such as del(17p), t(4;14), amp(1q) and MYC translocations, and the International Staging System (ISS) to generate a risk score able to better identify high-risk patients experiencing relapse and premature death [15] . Although an external validation of this predictive tool is required, the Authors envisaged an easy incorporation of the detection of these molecular markers in a diagnostic test that could be developed in the everyday practice.
Beyond mutations affecting single genes, the prognostic power of patients' global mutational load is uncertain. Indeed, while Bolli et al. reported a positive correlation between the amount of variants and the extent of the risk of relapse and death [14] , Weinhold and colleagues found no association between the mutational load and GEP70 risk status either at presentation or relapse, after adjustment for the UAMS (University of Arkansas for Medical Sciences) molecular calssification [31, 40].
Therapy
Concerning the therapeutic implications of the application of NGS-based technologies in MM, it is conceivable that the definition of MM mutational landscape may help towards the identification of specific treatments from which patients may particularly benefit, or otherwise to be avoided. This could be the case of patients carrying mutations associated with a clinical response to specific therapies or representing druggable targets. NRAS, IRF4 and EGR1 are examples of genes that, when mutated, seemed to be associated with a different response to treatments currently used in myeloma. In particular, an association was reported between the reduced sensitivity to bortezomib and the presence of NRAS mutations at relapse, having a negative impact on both response rate and time to progression [41], whereas IRF4 and EGR1 mutations correlated with better outcome with immunomodulatory agent therapy [15] . was used to overcome resistance to vemurafenib [46] .
Furthermore, clonal heterogeneity might represent a major obstacle to the success of targeted therapies pinpointed to one genetic lesion. Indeed treatment directed against a mutation carried only by a subset of tumor cells is expected to be effective exclusively on that subclone, with a consequent restricted clinical benefit, which makes at least necessary to resort to a combination of different types of treatment targeting distinct subclones.
On the other hand, even genes mutated in most of the tumor population do not necessarily have an important biological impact. Targeted treatment based solely on DNA sequencing data, in fact, could be ineffective if that mutated gene is not expressed. Indeed, a recent RNA-seq analysis of a subset of patients who had previously undergone WES showed that most of the reported mutated genes have very low or undetectable expression [47] .
Response assessment
NGS could also meet another strong need that is emerging in the management of MM patients, i.e.
the determination of minimal residual disease (MRD) [48, 49] . While achievement of a morphological and serological complete remission was rare in the past, novel treatments have resulted in an increased occurrence of these events so that nearly all patients show a response to treatment and most achieve a complete response (CR) [50] . However, the increased effectiveness of treatment approaches in the past decade has not been accompanied by a better definition of CR, which conversely remains based on conventional serological and morphologic techniques, with the result that most patients achieving CR ultimately relapse and die. This scenario is mainly attributable to the persistence of MRD undetected by conventional response assessment methods [49] . Newer and more sensitive techniques to detect MRD in BM aspirates include multiparameter flow-cytometry (MFC), allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) and NGS. Although currently none of these techniques fully satisfies all the characteristics that the ideal MRD test should possess (i.e., high applicability, high sensitivity and specificity, good feasibility, easy accessibility, requirement for a limited sample, reproducibility, and proven clinical outcome), NGS fulfills most of them. In particular, MRD assessment by NGS is mainly, although not exclusively, based on the LymphoSIGHT platform (Adaptive Biotechnologies), which consists in genomic DNA amplification by multiplexed PCR assays using consensus primer sets allowing the recognition of all known alleles of the germline IGH and IGK sequences, followed by sequencing and identification of cancer-associated clonotypes with a minimum frequency of 5% [51] . The tumor-derived sequences detected in the samples at diagnosis are used as targets in follow-up samples to assess the presence of MRD, defined as the number of cancer-derived molecules per one million cell equivalents. Compared with ASO-PCR, NGS-based MRD assessment proved to be at least comparable in terms of sensitivity [52] , and recent studies in chronic lymphocytic leukemia and acute lymphoblastic leukemia indicated that a sensitivity of one in 1,000,000 is achievable by NGS when higher amounts of DNA are used [53, 54] . Furthermore, contrary to ASO-PCR, NGSbased monitoring of MRD does require neither use of patient-specific primers, nor creation of a standard curve for quantitation. This latter and other limitations of quantitative ASO-PCR could be overcome, at the same performance level, by droplet digital PCR, especially in terms of reduced labor intensiveness and easier data interpretation, although its potential advantages and predictive value need to be further studied in the context of prospective clinical trials [55] . On the other hand, compared with NGS, MFC has the advantages of requiring less time to generate results, of being virtually applicable to all patients, and of not requiring a baseline sample. However, although a sensitivity higher than 10 -5 is achievable by means of the new MFC instruments, up to 2x10 6 cells are required. In addition, further efforts are needed to conform the flow-based approaches and limit the subjectivity linked to individual interpretations. Finally, the need to work on fresh samples makes the transfer of MFC in clinical settings more complex. Nevertheless, NGS too has limitations: besides that fact that it can be limited in its ability to capture a clonotype in all patients in spite of adequate samples, there are still several issues with quantification, among which the calibration and correction approaches used to determine total leukocytes, B-lineage cell numbers, and reproducibility of quantification (in particular considering that it depends on DNA quantity and sequencing depth) [56] . Furthermore, additional checks are required to determine whether a negative result is attributable to sample quality (e.g., morphology and/or flow cytometry).
The clinical significance of sequencing-based MRD assessment in MM patients was recently reported in two studies by the same group [51, 57] . In particular, the most recent one adopted an in-house deep-sequencing method using the standardized primers developed by the Biomed-2 concerted action to amplify all IGH or IGK sequences in a patient sample [58] . Differently from the proprietary multiplex PCR entailed by the LymphoSIGHT method, to be performed at centralized laboratories, this approach can be implemented in any laboratory with NGS capability, thus shortening turn-around time, and can be fully automated, and hence easily standardized reducing inter-lab variation [57] . 
Expert commentary
The exploitation of NGS-enabled mutational characterization of cancer patients in therapeutic field has as its ultimate goal the implementation of precision medicine, i.e. the administration of personalized treatment based on the mutational repertoire of each tumor. This process is often referred to as matching the right drug to the right patient in the right dose at the right time. A major obstacle to its implementation, however, is the inadequacy of many current clinical trial designs.
Such inadequacy is related to the fact that targeted approaches rely on increasing amounts of therapeutic agents, whose potential combinations and conceivable sequential administration options are even exponentially more numerous. Furthermore, myeloma, like most cancers, is not a molecularly homogeneous entity, but rather presents several actionable mutations and does not nicely segregate into genomically-defined subtypes that could be used to stratify treatment arms [60] . In other words, the similarity between patients and the homogeneity between therapy groups required for classical clinical trials seem irreconcilable with the molecular intra-and inter-tumor diversity and different therapeutic options that constitute the basis of personalized medicine. The resulting combinatorial complexity makes it necessary to extend the conventional "basket" and "umbrella" approaches developed to study molecularly targeted therapies [61] and to resort at least to adaptive designs enabling an ongoing modification of the clinical trial based on the knowledge acquired through the trial itself [62] . Even better, precision medicine would require a kind of clinical trial focusing on single, not average, treatment responses, and probing the myriad factors that shape an individual's response to a specific therapy [63] . Such a personalization of clinical trials might rely on the implementation of oncological N-of-1 trials (which should all be evenly carried out and whose results should be aggregated), although there is skepticism towards this approach in part of the oncology community, including regulatory agencies, researchers and clinicians [64] .
Beyond the paradigm shift in clinical trial design needed to fit studies able to effectively assessing targeted agents into the regulatory drug approval pathway, another obstacle to the realization of precision oncology is the amount of data that must be taken into account and integrated, including high-quality NGS data, histopathological and clinical findings. The impossibility of processing and interpretation of such a data volume in a meaningful and timely manner by clinicians raises the need for machine-learning approaches intended to assist oncologists responsible of taking decisions about the treatment of single patients. IBM's Watson
Oncology is one of these computing self-learning algorithms currently being tested at some institutions [65, 66] .
In our opinion, those just discussed are the main considerations to be made when thinking about a future pervasive application of NGS-enabled tailored medicine in MM, but certainly many others exist. After all, precision oncology represents an epochal revolution in patients' management, and therefore it is conceivable that it involves substantial changes (at both cultural and practical levels) in the way we operate in order to cure cancer, that surely will need a long time to be realized. The concerted effort of all stakeholders involved in the development of precision oncology (researchers, clinicians, regulatory agencies, governments) is now mandatory to ensure that in the future it will become a reality in routine clinical practice.
Five-year view
Considering that the continuous improvement of sequencing technologies will most likely reduce Continuing to speculate on the future evolution of NGS technology in MM, RNA-sequencing is an application of NGS still largely unexplored in the context of the disease [47, 75] , and that reasonably will produce a substantial amount of new data in the near future.
In particular, RNA-seq could allow a deeper characterization of coding transcriptome than that obtained by means of microarrays, by providing information, as well as on gene expression levels, on differential splicing and isoform expression, mutational profiling and gene fusions. This could be particularly meaningful in MM, where disease-specific alternate splicing events of several genes have been reported [76, 77, 78] . Moreover, RNA-seq is the technology of choice for the discovery and genome-wide expression analysis of non-coding RNAs, whose involvement in MM is increasingly documented and that are being investigated as a therapeutic target [79, 80] . 
Key issues
• MM is a malignant proliferation of antibody-secreting bone marrow plasma cells characterized by a wide clinical presentation and an extremely heterogeneous genetic background. Despite the recent improvement of patient outcome and quality of life thanks to new efficient drugs, the majority of patients experiences relapse, and the actually recommended risk stratification at diagnosis fails to identify a subgroup of high-risk cases.
• Recently, the genetic makeup of MM cells is being better characterized by means of NGS technologies, with the aim of defining new markers for improved risk prediction and to guide towards the most appropriate therapeutic strategy.
• The general scenario emerging form WGS/WES studies indicates a few genes found mutated at a significant frequency of occurrence, among which KRAS, NRAS, BRAF, TP53, DIS3 and FAM46C. Besides the MAPK pathway, that is the most recurrently mutated, the non-canonical NF-kB signalling is another key target of somatic mutation in MM.
• Different processes, among which kataegis and aberrant somatic hypermutations, are involved in the generation of MM mutational repertory, whose relative contribution may vary in time.
• Nearly all patients had evidence of clonal heterogeneity. Even known driver mutations can be subclonal in some patients. An analysis at the single-cell level provided clear evidence of convergent evolution, consisting in the acquisition of redundant mutations conferring growth advantages by distinct clones. Although the genetic complexity increases with disease stage, clonal heterogeneity appears to be a premature event in MM pathogenesis and critical for disease progression.
• The application of massively parallel sequencing revealed, along with the traditional model of genomic aberrations linearly accumulated over time, a Darwinian branching model of tumor evolution, with several clonal progenitors present at diagnosis whose dominance alternates over time under selective pressures exerted by microenvironment or therapy.
• The information made available by the application of NGS technologies in MM is potentially reflected in the clinical setting at various levels, including i) prognostic stratification; ii) therapeutic choices; iii) response assessment.
i) Prognostication: a risk score with improved capacity to identify high-risk patients has been generated by combining some new mutation prognostic markers, adverse cytogenetic abnormalities and ISS [15] .
ii) Therapeutic choices: in terms of therapeutic applications of NGS-derived data, the most appealing perspective is directing treatment specifically to driver mutations, by means of agents selectively inhibiting the mutated or activated oncogene. The most recent and comprehensive WES study in MM overall detected potentially druggable mutations in 309 target genes and involving 53% of patients [15] . Although tailored therapies are promising, some biological aspects of the disease that may limit severely their effectiveness must be taken into consideration, first of all clonal heterogeneity.
iii) In 2016, the IMWG revised the response criteria for myeloma and included MRD negativity as the highest degree of response to treatment. Sequencing-based MRD assessment fulfills almost all the characteristics that the ideal MRD test should possess, and its clinical significance is recently being reported [51, 57] .
• Two major obstacles to the implementation of precision oncology in myeloma management are the inadequacy of many current clinical trial designs and the amount of data that must be taken into account and integrated, including high-quality NGS data, histopathological and clinical findings. The concerted effort of all stakeholders involved in the development of precision oncology (researchers, clinicians, regulatory agencies, governments) is mandatory to ensure that in the future it will become a reality in routine clinical practice.
• Some preliminary attempts aimed at introducing NGS-based technologies during routine diagnostic workup for MM have been made [68, 69, 70, 71] , and certainly will continue to be implemented.
• [15] and found mutated in at least 1% of patients when averaging the frequencies reported by Walker et al. [15] ,Bolli et al. [14] , and Lohr et al. [13] .
